June 2021

publicationMR-proADM / COVID-19

Midregional proadrenomedullin safely reduces hospitalization in a low severity cohort with infections in the ED: a randomized controlled multi-centre interventional pilot study

The midregional fragment of proadrenomedullin (MR-proADM) is known to provide accurate short-, mid- and long term prognostic information in the triage and multi-dimensional risk assessment of patients in the emergency department (ED). In two independent observational cohorts MR-proADM values identified low disease severity patients without risk of disease progression in the ED with no 28 days mortality that wouldn´t require hospitalization...
Gonzalez Del Castillo, J et al., Eur J Intern Med. 2021 Jun;88:104-113 >


May 2021

publicationMR-proADM / COVID-19

MR-proADM as marker of endotheliitis predicts COVID-19 severity

Early identification of patients at high risk of progression to severe COVID-19 constituted an unsolved challenge. Although growing evidence demonstrates a direct association between endotheliitis and severe COVID-19, the role of endothelial damage biomarkers has been scarcely studied...
Guadiana-Romualdo, L et al., Eur J Clin Invest. 2021 May;51(5):e13511 >


April 2021

press-releaseFinancial Reports

Thermo Fisher Scientific Reports First Quarter 2021 Results

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 3, 2021....
Thermo Fisher Scientific Reports First Quarter 2021 Results >


March 2021

publicationMR-proADM / COVID-19

Mid-regional pro-adrenomedullin as a supplementary tool to clinical parameters in cases of suspicion of infection in the emergency department

The review provides evidence related to MR-proADM as a triaging tool in avoiding unnecessary admissions to hospital and/ or inadequate discharge, and identifying patients most at risk of deterioration. It also covers the use of MR-proADM in the context of COVID-19...
Saeed, K et al., Expert Rev Mol Diagn. 2021 Apr;21(4):397-404 >


February 2021

press-releaseFinancial Reports

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2020 Results

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2020...
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2020 Results >


January 2021

publicationMR-proADM / COVID-19

The vasoactive peptide MR-pro-adrenomedullin in COVID-19 patients: an observational study

Increased levels of MR-proADM on admission and during hospital stay were independently associated with in-hospital mortality and may allow a better risk stratification, and particularly rule-out of fatal outcome, in COVID-19 patients...
Gregoriano,C et al., CCLM 2020-1295 >


News Archive